Search results
Results From The WOW.Com Content Network
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...
Laryngeal papillomatosis, also known as recurrent respiratory papillomatosis (RRP) or glottal papillomatosis, is a rare medical condition in which benign tumors form along the aerodigestive tract. [ 1 ] [ 2 ] There are two variants based on the age of onset: juvenile and adult laryngeal papillomatosis. [ 3 ]
The presence of HPV in the tumour is associated with a better response to treatment and a better outcome, independent of the treatment methods used, and a nearly 60% reduced risk of dying from the cancer. Most recurrence occurs locally and within the first year after treatment. The use of tobacco decreases the chances of survival.
Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse. [1]
Myhre syndrome is due to mutations in the SMAD4 gene. [3] This gene encodes a protein - transducer mediating transforming growth factor beta. Some researchers believe that the SMAD4 gene mutations that cause Myhre syndrome impair the ability of the SMAD4 protein to attach (bind) properly with the other proteins involved in the signaling pathway.
Papillary renal cell carcinoma (PRCC) is a malignant, heterogeneous tumor originating from renal tubular epithelial cells of the kidney, which comprises approximately 10-15% of all kidney neoplasms. [1] Based on its morphological features, PRCC can be classified into two main subtypes, which are type 1 and type 2 (eosinophilic). [2]
[20] [12] However, recurrence of TGCT after surgery is common, [18] with a higher rate of recurrence for diffuse TGCT than for localized TGCT. [5]: 361 In cases of recurrent or resistant disease, multiple surgeries, total joint arthroplasties, or amputation may be required. [10]: 1